文献速递心脑血管急症

颅外-颅内搭桥术与症状性动脉闭塞患者卒中及死亡风险:CMOSS随机临床试验

Extracranial-Intracranial Bypass and Risk of Stroke and Death in Patients With Symptomatic Artery Occlusion: The CMOSS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论在症状性颈内动脉或大脑中动脉闭塞伴血流动力学不足的患者中,在药物治疗基础上加行颅外-颅内搭桥术未显著改变30天内卒中或死亡或30天后至2年同侧缺血性卒中的复合结局风险。

CMOSS试验在中国13个中心纳入324例因血流动力学不足导致短暂性脑缺血发作或非致残性缺血性卒中的颈内动脉或大脑中动脉闭塞患者,随机接受搭桥手术加药物治疗(手术组,n=161)或单纯药物治疗(药物组,n=163)。主要复合终点(30天内卒中或死亡或30天后至2年同侧缺血性卒中)发生率手术组8.6%(13/151) vs 药物组12.3%(19/155),差异无统计学意义(HR 0.71,95%CI 0.33-1.54,P=0.39)。9项次要终点均无显著差异,包括2年内任何卒中或死亡(9.9% vs 15.3%,HR 0.69,95%CI 0.34-1.39,P=0.30)和2年内致死性卒中(2.0% vs 0%,P=0.08)。作者结论认为,在该人群中加用搭桥手术未显著改变主要复合结局风险。

要点

  • 主要复合终点(30天内卒中或死亡或30天后至2年同侧缺血性卒中):手术组8.6%(13/151) vs 药物组12.3%(19/155),HR 0.71(95%CI 0.33-1.54),P=0.39,差异无统计学意义。
  • 30天内卒中或死亡风险:手术组6.2%(10/161) vs 药物组1.8%(3/163);30天后至2年同侧缺血性卒中风险:手术组2.0%(3/151) vs 药物组10.3%(16/155)。
  • 2年内任何卒中或死亡:手术组9.9%(15/152) vs 药物组15.3%(24/157),HR 0.69(95%CI 0.34-1.39),P=0.30,无显著差异。
  • 2年内致死性卒中:手术组2.0%(3/150) vs 药物组0%(0/153),P=0.08,无显著差异。
  • 9项预设次要终点均无显著差异;作者结论认为在症状性ICA或MCA闭塞伴血流动力学不足患者中,药物治疗加搭桥手术未显著改变主要复合结局风险。

适用人群与场景

  • 纳入标准:颈内动脉(ICA)或大脑中动脉(MCA)动脉粥样硬化性闭塞,伴有因血流动力学不足导致的短暂性脑缺血发作或非致残性缺血性卒中,基于CT灌注成像判定;年龄中位数52.7岁,男性257例(79.3%)。
  • 研究场景:中国13个中心,2013年6月至2018年3月招募,最终随访2020年3月18日。

诊断标准与关键阈值

  • 通过CT灌注成像判定血流动力学不足。

处置流程与药物剂量

  • 手术组:颅外-颅内搭桥手术加药物治疗(n=161);药物组:单纯药物治疗(n=163)。
  • 药物治疗包括抗血小板治疗和卒中危险因素控制。

研究设计与关键结果

  • 研究类型:随机、开放标签、结局评估者盲法试验,13个中心,324例患者(手术组161例,药物组163例),309例(95.4%)完成试验。
  • 主要复合终点(30天内卒中或死亡或30天后至2年同侧缺血性卒中):手术组8.6%(13/151) vs 药物组12.3%(19/155);发生率差-3.6%(95%CI -10.1%至2.9%);HR 0.71(95%CI 0.33-1.54);P=0.39。
  • 30天内卒中或死亡:手术组6.2%(10/161) vs 药物组1.8%(3/163)。
  • 30天后至2年同侧缺血性卒中:手术组2.0%(3/151) vs 药物组10.3%(16/155)。
  • 2年内任何卒中或死亡:手术组9.9%(15/152) vs 药物组15.3%(24/157);发生率差-5.4%(95%CI -12.5%至1.7%);HR 0.69(95%CI 0.34-1.39);P=0.30。
  • 2年内致死性卒中:手术组2.0%(3/150) vs 药物组0%(0/153);发生率差1.9%(95%CI -0.2%至4.0%);P=0.08。
  • 9项预设次要终点均无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。

对床旁实践的改变

  • 对于症状性ICA或MCA闭塞伴血流动力学不足的患者,在药物治疗基础上加用颅外-颅内搭桥手术未显著改变主要复合结局风险,作者结论认为该结果不支持常规加用搭桥手术来降低上述风险。

指南或共识出处

  • CMOSS随机临床试验(ClinicalTrials.gov Identifier: NCT01758614),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Prior trials of extracranial-intracranial (EC-IC) bypass surgery showed no benefit for stroke prevention in patients with atherosclerotic occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA), but there have been subsequent improvements in surgical techniques and patient selection.

OBJECTIVE: To evaluate EC-IC bypass surgery in symptomatic patients with atherosclerotic occlusion of the ICA or MCA, using refined patient and operator selection.

DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, open-label, outcome assessor-blinded trial conducted at 13 centers in China. A total of 324 patients with ICA or MCA occlusion with transient ischemic attack or nondisabling ischemic stroke attributed to hemodynamic insufficiency based on computed tomography perfusion imaging were recruited between June 2013 and March 2018 (final follow-up: March 18, 2020).

INTERVENTIONS: EC-IC bypass surgery plus medical therapy (surgical group; n = 161) or medical therapy alone (medical group; n = 163). Medical therapy included antiplatelet therapy and stroke risk factor control.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of stroke or death within 30 days or ipsilateral ischemic stroke beyond 30 days through 2 years after randomization. There were 9 secondary outcomes, including any stroke or death within 2 years and fatal stroke within 2 years.

RESULTS: Among 330 patients who were enrolled, 324 patients were confirmed eligible (median age, 52.7 years; 257 men [79.3%]) and 309 (95.4%) completed the trial. For the surgical group vs medical group, no significant difference was found for the composite primary outcome (8.6% [13/151] vs 12.3% [19/155]; incidence difference, -3.6% [95% CI, -10.1% to 2.9%]; hazard ratio [HR], 0.71 [95% CI, 0.33-1.54]; P = .39). The 30-day risk of stroke or death was 6.2% (10/161) in the surgical group and 1.8% (3/163) in the medical group, and the risk of ipsilateral ischemic stroke beyond 30 days through 2 years was 2.0% (3/151) and 10.3% (16/155), respectively. Of the 9 prespecified secondary end points, none showed a significant difference including any stroke or death within 2 years (9.9% [15/152] vs 15.3% [24/157]; incidence difference, -5.4% [95% CI, -12.5% to 1.7%]; HR, 0.69 [95% CI, 0.34-1.39]; P = .30) and fatal stroke within 2 years (2.0% [3/150] vs 0% [0/153]; incidence difference, 1.9% [95% CI, -0.2% to 4.0%]; P = .08).

CONCLUSIONS AND RELEVANCE: Among patients with symptomatic ICA or MCA occlusion and hemodynamic insufficiency, the addition of bypass surgery to medical therapy did not significantly change the risk of the composite outcome of stroke or death within 30 days or ipsilateral ischemic stroke beyond 30 days through 2 years.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01758614.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ma Y, Wang T, Wang H, et al. Extracranial-Intracranial Bypass and Risk of Stroke and Death in Patients With Symptomatic Artery Occlusion: The CMOSS Randomized Clinical Trial. JAMA. 2023. PMID: 37606672. doi:10.1001/jama.2023.13390

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。